Interferometric Space Missions for the Search for Terrestrial Exoplanets: Requirements on the Rejection Ratio

The requirements on space missions designed to study Terrestrial exoplanets are discussed. We then investigate whether the design of such a mission, specifically the Darwin nulling interferometer, can be carried out in a simplified scenario. The key element here is accepting somewhat higher levels of stellar leakage. We establish detailed requirements resulting from the scientific rationale for the mission, and calculate detailed parameters for the stellar suppression required to achieve those requirements. We do this utilizing the Darwin input catalogue. The dominating noise source for most targets in this sample is essentially constant for all targets, while the leakage diminishes with the square of the distance. This means that the stellar leakage has an effect on the integration time only for the nearby stars, while for the more distant targets its influence decreases significantly. We assess the impact of different array configurations and nulling profiles and identify the stars for which the detection efficiency can be maximized.Comment: 21 pages, 8 figures; TBP in Astrophysics and Space Science 200

Egg length of Anastrepha obliqua Macquart (Diptera, Tephritidae) according to oviposition rate and maternal age

The length of the entire egg, micropile and vitellus regions of Anastrepha obliqua Macquart, 1835 were measured during all opposition period. Obtained values were compared among them and with oviposition rate. The smallest eggs were produced during the first 35 oviposition days, period where the highest oviposition rate occured. The decrease in egg length was found to be due to a descrease in the vitellus region. Micropile length was found to be pratically constant throughout oviposition. Furthermore, no relationship between maternal age and length was detectable

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)